NCT00140452View on ClinicalTrials.gov

Phase II Study Using Thalidomide for the Treatment of ALS

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2005

Study Completion Date

November 30, 2007

Conditions
Amyotrophic Lateral SclerosisALS
Interventions
DRUG

Thalidomide

Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.

Trial Locations (1)

03756

Dartmouth Hichcock Medical Center, Lebanon

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER